Jiukuan Hao

Dr. Jiukuan Hao


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 August 2021 in Frontiers in Aging Neuroscience
Verified
Journal Article
Open access
XXXiaotian Xu
Xiaotian Xu
LDLin Du
Lin Du
JJJianxiong Jiang
Jianxiong Jiang
MYMing Yang
Ming Yang
ZWZhaoxia Wang
Zhaoxia Wang
JHJiukuan Hao
Jiukuan Hao
Growing evidence suggests that hypertension and aging are prominent risk factors for the development of late-onset Alzheimer’s disease (LOAD) by inducement of neuroinflammation. Recent study showed that neuroinflammation via activated microglia induces reactive astrocytes, termed A1 astrocytes, that highly upregulate numerous classical complement cascade genes that are destructive to neurons in neurodegeneration diseases. Moreover, triggering receptor expressed on myeloid cells 2 (TREM2) is considered as one of the strongest single-allele genetic risk factors and plays important roles in neuroinflammation for LOAD. However, the mechanisms of microglia in the regulation of A1 astrocytic activation are still not clear. We introduced angiotensin II-induced hypertension in middle-aged mice and found that hypertension-upregulated TREM2 expression and A1 astrocytic activation were involved in neuroinflammation in the animal models used in this study. The in vitro results revealed that overexpression of microglial TREM2 not only mitigated microglial inflammatory response but also had salutary effects on reverse A1 astrocytic activation and neuronal toxicity.

31 January 2022 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
CZChangwen Zhang
Changwen Zhang
ASAyyiliath M. Sajith
Ayyiliath M. Sajith
XXXiaotian Xu
Xiaotian Xu
JJJianxiong Jiang
Jianxiong Jiang
JBJ. Phillip Bowen
J. Phillip Bowen
JHJiukuan Hao
Jiukuan Hao

18 May 2022 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
XXXiaotian Xu
Xiaotian Xu
CZChangwen Zhang
Changwen Zhang
JJJianxiong Jiang
Jianxiong Jiang
MXMei Xin
Mei Xin
JHJiukuan Hao
Jiukuan Hao

3 June 2025 in Fluids and Barriers of the CNS
Verified
Journal Article
Open access
PDF file
AAAdnan Akif
Adnan Akif
TNThi Thanh My Nguyen
Thi Thanh My Nguyen
LLLangni Liu
Langni Liu
XXXiaotian Xu
Xiaotian Xu
AKAmol Kulkarni
Amol Kulkarni
JHJiukuan Hao
Jiukuan Hao
Background: As a key inflammatory factor, the nucleotide-binding oligomerization domain (NOD)-like receptor protein 3 (NLRP3) inflammasome plays a crucial role in neuroinflammation and the progression of neurodegenerative diseases. Dysregulation of NLRP3 signaling can trigger various inflammatory responses in the brain, contributing to the development of neurodegenerative diseases such as ischemic stroke, vascular dementia (VaD), Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS). Therefore, the NLRP3 signaling pathway is a promising therapeutic target for the treatment of neurodegenerative diseases, including VaD. Methods: In this study, we investigated the therapeutic effects of a synthetic sulfonylurea NLRP3 inhibitor, AMS-17, in a VaD mouse model using bilateral common carotid artery stenosis (BCAS) and elucidated the underlying mechanisms. All mice were randomly divided into three groups: Sham, VaD + Vehicle, and VaD + AMS-17. Cognitive function was assessed using the Y-maze and Morris water maze (MWM) on the 50th day after BCAS. Brain sections and blood serum samples were collected for biomarker analysis and immunohistochemistry. Neurodegeneration, expressions of the molecules involved in the NLRP3 signaling pathways, tight junction proteins, and myelination were assessed using western blotting and immunofluorescence (IF). The levels of Interleukin-1 beta (IL-1β), Tumor Necrosis Factor-alpha (TNF-α) and Interleukin-4 (IL-4) in the blood were measured using ELISA. Results: AMS-17 treatment improved cognitive function, enhanced blood-brain barrier (BBB) integrity, and promoted remyelination in VaD mice. Additionally, AMS-17 reduced neurodegeneration and decreased the expression of NLRP3 and its associated proteins, Apoptosis-associated speck-like protein (ASC), and cleaved caspase-1 in the brain. It also lowered pro-inflammatory TNF-α and IL-1β levels, while increasing the anti-inflammatory IL-4 level in the blood. Conclusions: The findings of this study provide the first promising evidence for the use of AMS-17 in VaD treatment in mice. This study introduces AMS-17 as a novel chemical scaffold with NLRP3 inhibitory activity, which can be further developed for the treatment of VaD in humans. Clinical trial number: Not applicable. Graphical

20 December 2021 in Brain Research Bulletin
Verified
Journal Article
Closed access
HFHefei Fu
Hefei Fu
JWJiapeng Wang
Jiapeng Wang
JWJie Wang
Jie Wang
LLLangni Liu
Langni Liu
JJJianxiong Jiang
Jianxiong Jiang
JHJiukuan Hao
Jiukuan Hao

3 August 2021 in Research Square
Verified
Preprint
Open access
PDF file
XXXiaotian Xu
Xiaotian Xu
CZChangwen Zhang
Changwen Zhang
JJJianxiong Jiang
Jianxiong Jiang
MXMei Xin
Mei Xin
JHJiukuan Hao
Jiukuan Hao
Background: As important components of the blood-brain barrier (BBB), brain endothelial cells (ECs) interact with pericytes, astrocytes, neurons, microglia and extracellular matrix in the neurovascular unit to maintain central nerve system (CNS) homeostasis and regulate neurological functions. Pathological changes in brain endothelium plays an important role in progression of ischemic stroke. The compromised BBB under ischemic stroke condition causes neuronal damage. However, the pathophysiological mechanisms of BBB in normal and under ischemic stroke condition has not been fully elucidated.Methods: C57bl/6 mice were subjected to 1-hour transient middle cerebral occlusion (tMCAO) model, and collected the brain samples after reperfusion for 24hours, 72hours and 1week. Lentivirus (YAP/TAZ shRNA), adenovirus (YAPS112A), TDP43 siRNA, TDP43-CTFS35 overexpression plasmid, Oxygen-glucose deprivation (OGD), and lipopolysaccharides (LPS) were applied to brain endothelial cells in vitro experiments. Brain endothelial cells (ECs) functions were tested by cell proliferation, migration and cell viability. Hippo signaling pathway was examined by immunofluorescence and western blotting.Results: The present study demonstrates that TDP43 is an essential gene to regulate brain ECs normal function, and knockdown of TDP43 reduces tight junction protein expression and inhibits brain ECs migration. Furthermore, ischemic injury and inflammation induce cytoplasmic TDP43-CTFS35 aggregation brain ECs, which weaken TDP43 full-length’s function leading to impairing tight junction (TJ) protein expression and cell migration. The expression of cytoplasmic TDP43-CTFS35 in brain ECs increased at 24 hours and 72 hours after MCAO, but disappeared at 1 week after MCAO. The expressions of TJ proteins, ZO-1 and claudin-5, and expression of P-YAP are associated with the dynamic changes of TDP43-CTFS35 expression in brain ECs after MCAO. The underlying mechanism of TDP43-CTFS35’s effects on brain ECs is that TDP43-CTFS35 turns off the Hippo signaling pathway by inhibition of PMST1/2 phosphorylation leading to de-phosphorylate YAP, and subsequently causes brain ECs functional changes.Conclusions: The present study provides new insight knowledge regarding the mechanisms of brain vascular ECs regulation and pathological change in the BBB after cerebral ischemic injury.